ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Anadys Pharmaceuticals (MM)

Anadys Pharmaceuticals (MM) (ANDS)

3.70
0.00
(0.00%)
Closed March 27 04:00PM
3.70
0.00
( 0.00% )
Pre Market: 08:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
3.70
Bid
0.00
Ask
0.00
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
3.70
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

ANDS Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AVTXAvalo Therapeutics Inc
$ 17.74
(273.47%)
389.68k
BCGBinah Capital Group Inc
$ 20.16
(112.21%)
119.71k
PIKKidpik Corporation
$ 5.37
(64.22%)
1M
SSKNStrata Skin Sciences Inc
$ 0.66
(48.35%)
2
KTRAKintara Therapeutics Inc
$ 0.1232
(37.65%)
8.78M
WAVDWaveDancer Inc
$ 2.93
(-18.61%)
10
UGROUrban Gro Inc
$ 1.48
(-18.46%)
393
INOInovio Pharmaceuticals Inc New
$ 10.65
(-18.27%)
33
SOBRSOBR Safe Inc
$ 0.41
(-18.00%)
1.49k
MLKNMillerKnoll Inc
$ 25.25
(-17.29%)
1.72k
KTRAKintara Therapeutics Inc
$ 0.1228
(37.21%)
8.79M
AKBAAkebia Therapeutics Inc
$ 2.65
(18.30%)
2.23M
GMDAGamida Cell Ltd
$ 0.0505
(-14.70%)
1.24M
CISSC3is Inc
$ 0.0364
(-4.71%)
1.22M
PIKKidpik Corporation
$ 5.37
(64.22%)
1M

ANDS Discussion

View Posts
alvaroc2 alvaroc2 12 years ago
Hello, someone thinks Roche can surpass the actual offer at 3.7 if somes investor don't accept the offer? 5? opinions?, thankyou in advance.
👍️0
Hedge Starz Hedge Starz 12 years ago
about half a year ago i made note that ANDS was a play that if i had $100k to lay down for a big winner.....ANDS was on the short list. I didn't get to hit it big here

BUT I WANT TO CONGRATULATE ANYONE WHO MADE BIG MONEY HERE! Well done. q lead us to this 2nd half of 2011 for big things and we had insider buying from qvc fund the whole time. Way to go people
👍️0
JohnnyCasino JohnnyCasino 12 years ago
So true alvaroc, the discoveries these companies are making may directly benefit our children in their lives
I also recently began reading Surfs posts and continue to learn much from Sheff Station board. Good Luck to you and yours
👍️0
alvaroc2 alvaroc2 12 years ago
Your welcome JohnnyCasino, I am so happy for the reward and for the advance in the search to cure HEPC and others diseases like cancer, unfortunately I lost to many people of may family of cancer, I hope some of this companys can cure this, I have invested in IDIX INHX GNBT and PPHM, thank you to surf and others members, regards.
👍️0
JohnnyCasino JohnnyCasino 12 years ago
Well done alvaroc
Thank you for your post
Also appreciate the heads up from Sheff
and the gentlemen posting on his board
Solid information, Great day today
👍️0
mlkrborn mlkrborn 12 years ago


Roche's All-Oral Hep C Therapy Could Be First, Not Best, to Reach Market

*
Inhibitex Inc.| INHX
UP
*
Vertex Pharmaceuticals| VRTX
DOWN
*
Achillion Pharmaceuticals Inc.| ACHN
UP

SAN DIEGO (TheStreet) -- Roche(RHHBY) is buying Anadys Pharmaeuticals(ANDS_) for $230 million to bolster its pipeline of experimental hepatitis C drugs, the company said Monday.

Anadys shareholder will receive $3.70 per share in cash from Roche, which represents a 256% premium over Anadys' closing price of $1.04 per share on Friday.

By acquiring Anadys, Roche hopes to develop safer, convenient and all-oral treatments for hepatitis C that do not the use of injectable interferon -- a goal shared by all of the major drug makers pursuing new hepatitis C therapies.

Anadys' most advanced hepatitis C drug candidate is a pill known as setrobuvir. Results from a mid-stage study testing setrobuvir in combination with injectable interferon and ribavirin, another oral hepatitic C medicine, were announced last Thursday.

On a conference call Thursday, Anadys' executives insisted that the phase II results demonstrated setrobuvir's potential to be part of a future combination therapy against hepatitis C. Yet Anadys' share price barely moved after the setrobuvir data were released last week, suggesting investors took a dimmer view of the drug's prospects.

Other small, independent hepatitis C drug makers may react in sympathy Monday as investors anticipate more deal-making activity in hepatitis C. Idenix Pharmaceuticals(IDIX_), Inhibitex(INHX_) and Achillion Pharmaceuticals(ACHN_) are all developing hepatitis C drugs that could potentially be a part of an all-oral, interferon-free regimen being pursued by larger drug companies such as Merck(MRK_), Johnson & Johnson(JNJ_), Abbott Labs(ABT_) and Bristol-Myers Squibb(BMY_).

Pharmasset(VRUS_) is the best-performing biotech stock this year due to the excitement over its hepatitis C drug candidates. Yet the Anadys acquisition may be perceived as a negative given Roche's existing hepatitis C partnership with Pharmasset. Investors will inevitably ask why Roche didn't acquire Pharmasset, although with a current market value of almost $6 billion, Roche may have deemed Pharmasset to be too expensive.

In addition to setrobuvir, Roche's portfolio of hepatitis C drugs includes danoprevir, which it acquired from InterMune last year; RG7128 (the drug partnered with Pharmasset); and wholly owned RG7432. Roche, of course, also sells the Pegasys, the market-leading interferon.

The Anadys deal may also up the pressure on existing hepatitis C powerhouse Vertex Pharmaceuticals(VRTX_) to seek out new deals to develop an all-oral therapy. The commercial launch of Vertex's new, powerful hepatitis C drug Incivek has been a success but the drug must be combined with interferon and ribavrin. Vertex has a next generation hepatitis C drug, VX-222, in clinical testing but has not yet been able to find a way to make that drug work without the need for interferon.

--Written by Adam Feuerstein in Boston.
👍️0
I Love Roth Iras I Love Roth Iras 12 years ago
Congrats ANDS shareholders.....nice day for you guys, enjoy it.
👍️0
surf1944 surf1944 12 years ago
1:57AM Anadys Pharma agress to be acquired by Roche (RHHBY) for $3.70 per share (ANDS) 1.04 : Co announces it has entered into a definitive merger agreement to be acquired by Roche (RHHBY). Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at $3.70 per share and represents a 256% premium over the closing price of $1.04 on October 14, 2011. The acquisition aims to expand future treatment options for hepatitis C patients.
👍️0
surf1944 surf1944 12 years ago
Anadys Announces Agreement To Be Acquired By Roche
Acquisition aims to expand future treatment options for hepatitis C patients

Press Release Source: Anadys Pharmaceuticals, Inc. On Monday October 17, 2011, 1:06 am EDT

SAN DIEGO, Oct. 17, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (NASDAQ:ANDS - News) today announced that it has entered into a definitive merger agreement to be acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger agreement, Roche will commence an all cash tender offer for all outstanding shares of common stock of Anadys at USD 3.70 per share.

The USD 3.70 per share cash offer price represents a 256% premium over the closing price of USD 1.04 on October 14, 2011.

Steve Worland, President and Chief Executive Officer of Anadys, said: "Since Anadys' formation, our focus has been on driving forward research and development that would make a real difference to the lives of patients, especially those with hepatitis. With Roche's considerable capabilities and experience in HCV, we believe this acquisition provides the best chance of success for the new potential treatments to reach patients. I would like to thank all our contributors for their dedicated efforts to advance the compounds to their current position."

Jean-Jacques Garaud, Global Head of Roche Pharma Research and Early Development, said: "This acquisition augments Roche's already strong HCV portfolio. Our aim is to offer physicians and hepatitis patients a powerful combination of therapies that bring us closer to a cure, even without the use of interferon. Anadys' compounds provide additional modes of action that could lead to interferon-free treatment regimens without viral resistance."

Anadys' Board of Directors determined that the merger agreement and the transactions contemplated thereby are advisable, fair to and in the best interests of Anadys and its stockholders, and recommends that Anadys' stockholders tender their shares and, if necessary, adopt the merger agreement.

Each of Anadys' directors and executive officers has agreed to tender their shares in the offer.

The closing of the tender offer will be subject to the tender of a number of shares that, together with the shares owned by Roche, represent a majority of the total number of outstanding shares (assuming the exercise of all vested and unvested options and warrants having an exercise price per share less than the tender offer price) and other customary conditions. In addition, the transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The tender offer is expected to close within the fourth quarter of 2011.

The terms and conditions of the tender offer will be described in the tender offer documents, which will be filed with the U.S. Securities and Exchange Commission ("SEC").

Lazard is acting as financial advisor to Anadys and Cooley LLP is serving as Anadys' legal advisor.
👍️0
invest2win invest2win 12 years ago
I knew this was one to buy.
👍️0
kei kei 12 years ago
(related article) Roche-Anadys Hookup Could Spark More Hep C Acquisitions
http://www.thestreet.com/_yahoo/story/11278574/1/roche-anadys-hookup-could-spark-more-hep-c-acquisitions.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
👍️0
alvaroc2 alvaroc2 12 years ago
Congratulations for all the shareholders of ANDS!!!!
👍️0
mlkrborn mlkrborn 12 years ago
ACHN $4.91 and ANDS $1.03 released positive news at the same time: Is this coincidence? interesting!
Anadys Pharma announces 'positive' 12-week data for Setrobuvir in Phase 2b Hepatitis C study (ANDS) 1.03 : Co released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients. Setrobuvir is the Company's direct-acting antiviral being developed for the treatment of chronic hepatitis C, or HCV. 78% of treatment-naive patients and 76% of patients who had responded inadequately to, or relapsed after, prior treatment with P/R had undetectable virus at week 12 while receiving setrobuvir plus P/R, compared to 56% and 44%, respectively, for patients who received placebo plus P/R. 71% of treatment-naive patients who received setrobuvir plus P/R had undetectable virus at week 8 and met the initial response-guided criteria for shortening treatment in this study to 28 weeks from the traditional 48 weeks for treatment with P/R alone. High Barrier to Resistance Confirmed. 29% of patients who had no appreciable response to prior treatment with P/R (null responders) achieved cEVR with setrobuvir plus P/R, and the percentage of patients with undetectable virus continued to climb in this hard-to-treat population to 36% at week 18. No prior null responders received placebo plus P/R in this trial.

Achillion Pharma announces nomination of second generation NS5A inhibitor for the treatment of Hepatitis C (ACHN) 4.91 : Co announced the nomination of an additional clinical candidate for the treatment of the hepatitis C virus from its NS5A inhibitor program. The candidate, ACH-3102, is a second generation NS5A inhibitor that in preclinical studies has demonstrated potent pan-genotypic activity against HCV genotypes 1 - 6, including excellent activity against both the genotype 1a subtype and known mutant variants of genotype 1 HCV.
👍️0
surf1944 surf1944 12 years ago
7:04AM Anadys Pharma announces 'positive' 12-week data for Setrobuvir in Phase 2b Hepatitis C study (ANDS) 1.03 : Co released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients. Setrobuvir is the Company's direct-acting antiviral being developed for the treatment of chronic hepatitis C, or HCV. 78% of treatment-naive patients and 76% of patients who had responded inadequately to, or relapsed after, prior treatment with P/R had undetectable virus at week 12 while receiving setrobuvir plus P/R, compared to 56% and 44%, respectively, for patients who received placebo plus P/R. 71% of treatment-naive patients who received setrobuvir plus P/R had undetectable virus at week 8 and met the initial response-guided criteria for shortening treatment in this study to 28 weeks from the traditional 48 weeks for treatment with P/R alone. High Barrier to Resistance Confirmed. 29% of patients who had no appreciable response to prior treatment with P/R (null responders) achieved cEVR with setrobuvir plus P/R, and the percentage of patients with undetectable virus continued to climb in this hard-to-treat population to 36% at week 18. No prior null responders received placebo plus P/R in this trial.
👍️0
alvaroc2 alvaroc2 12 years ago
N 10/13 11:00 *ANADYS REPORTS POSITIVE 12-WEEK DATA FOR SETROBUVIR IN PHASE 2B


+------------------------------------------------------------------------------+

Anadys Announces Positive 12-Week Data for Setrobuvir in Phase 2b Hepatitis C Study
2011-10-13 11:00:17.381 GMT

Anadys Announces Positive 12-Week Data for Setrobuvir in Phase 2b Hepatitis C
Study

- Strong Antiviral Response in Prior Partial Responders and Relapsers

- Favorable Safety Data with AE Profile Comparable to Control Group

- High Barrier to Resistance Confirmed

Conference Call at 8:00 AM EDT Today

PR Newswire

SAN DIEGO, Oct. 13, 2011

SAN DIEGO, Oct. 13, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq:
ANDS) today released interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with pegylated interferon and ribavirin (P/R) in genotype 1 hepatitis C patients.  Setrobuvir is the Company's direct-acting antiviral being developed for the treatment of chronic hepatitis C, or HCV.

"We are pleased with today's data, which we believe demonstrate a compelling profile for setrobuvir in significantly more patients," said Steve Worland, Ph.D., President and CEO of Anadys.  "The antiviral response in patients who had failed prior treatment is a particularly encouraging benchmark of setrobuvir's potency and high barrier to resistance.  Coupled with a favorable safety profile to date, we believe today's data position setrobuvir as a very attractive agent to be included in future DAA combination regimens."

78% of treatment-naive patients and 76% of patients who had responded inadequately to, or relapsed after, prior treatment with P/R had undetectable virus at week 12 (cEVR) while receiving setrobuvir plus P/R, compared to 56% and 44%, respectively, for patients who received placebo plus P/R.  71% of treatment-naive patients who received setrobuvir plus P/R had undetectable virus at week 8 and met the initial response-guided criteria for shortening treatment in this study to 28 weeks from the traditional 48 weeks for treatment with P/R alone.  

29% of patients who had no appreciable response to prior treatment with P/R (null responders) achieved cEVR with setrobuvir plus P/R, and the percentage of patients with undetectable virus continued to climb in this hard-to-treat population to 36% at week 18.  No prior null responders received placebo plus P/R in this trial.

The viral breakthrough rate through 12 weeks on setrobuvir plus P/R was low in both treatment-naïve patients (2.9%) and patients who had responded inadequately to, or relapsed after, prior treatment with P/R (3.6%).  The Company believes this low incidence of viral breakthrough exhibited to date in a larger patient population further characterizes setrobuvir's high barrier to resistance.

Setrobuvir has been generally well-tolerated in the study.  Safety data for patients receiving setrobuvir plus P/R, and comparison to the control group that received placebo plus P/R, are being reported through a time period that reflects a median dosing duration of 19 weeks.  The rate of discontinuing treatment in the study due to adverse events has been similar in patients receiving setrobuvir plus P/R (5.6%) or P/R alone (5.9%).  The profile of adverse events has been similar between the setrobuvir and control groups, with reported adverse events being typical for patients treated with interferon and ribavirin.  In the setrobuvir group, 39% of patients (84/215) developed a rash while 22% (15/68) of patients in the control group developed a rash.  98% of the rashes in the setrobuvir group were mild or moderate (grade 1 or grade 2), compared to 93% in the control group.  There were no Grade 4 rashes in either group.  The incidence of rash in the setrobuvir group is consistent with prior reports of rash due to interferon and ribavirin through 19 weeks of treatment.  

Proportion of patients with undetectable virus at Week 12 (cEVR)
setrobuvir + P/R placebo + P/R
Treatment-naive patients 78% 56%
Treatment-experienced patients
  prior partial responder or relapser 76% 44%
  prior null responder 29% ---

Phase 2b Protocol Design

283 patients were dosed in this study.  Patients received either setrobuvir 200 mg twice a day (bid) in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) (P/R) with a loading dose of setrobuvir 800 mg bid on day 1, or placebo plus P/R.  Patients who had a prior null response to P/R, defined as less than a 1 log10 decline in viral load at week 4 or less than a 2 log10 decline at week 12 during prior treatment, were not randomized to receive placebo.  All other patients were stratified by IL28B genotype
(CC/non-CC) between setrobuvir and placebo groups.  The interim antiviral response data is being reported as the proportion of patients with undetectable virus (< 15 IU/mL) using the Roche COBAS HCV TaqMan assay.  The primary endpoint of the study is Sustained Virological Response 24 weeks after patients conclude all treatment, known as SVR24.  In addition to the interim data released today, data through 24 weeks of dosing are expected around year-end.  The study is being conducted at sites in the United States, Canada, Australia and New Zealand.

Treatment-Naive Group

* 102 treatment-naive patients received setrobuvir plus P/R
* 36 treatment-naive patients received placebo plus P/R
* Treatment-naive patients who achieved undetectable levels of virus by Week
8 and maintain undetectable levels of virus are scheduled to conclude all
treatment at Week 28
* For treatment-naive patients with detectable virus at Week 8, treatment
with setrobuvir or placebo and P/R is scheduled to continue through Week
48  

Treatment-Experienced Group (including prior null responders)

* 82 patients who were partial responders during, or relapsers after, a
prior course of therapy with P/R alone received setrobuvir plus P/R
* 32 corresponding patients received placebo plus P/R
* 31 prior null responder patients received setrobuvir plus P/R
* All treatment-experienced patients are scheduled to be treated for 48
weeks  

About Setrobuvir

Setrobuvir is an HCV RNA polymerase inhibitor that belongs to a chemical class referred to as non-nucleosides.  Setrobuvir has a well-characterized safety database in which more than 350 subjects have received the agent to date.
 Setrobuvir has received Fast Track Status from the FDA for the treatment of chronic hepatitis C.  Earlier this year, Anadys announced a cross-company clinical trial agreement with a large, commercial-stage biopharmaceutical company to study setrobuvir in combination with another DAA in healthy volunteers.

Conference Call Webcast and Slides

Anadys will hold a conference call and webcast today, October 13, 2011 at 8:00 a.m. Eastern Daylight Time to discuss interim antiviral response and safety data from an ongoing Phase IIb study of setrobuvir in combination with P/R.  A live webcast of the call, including accompanying slides, will be available online at www.anadyspharma.com .  A telephone replay with slides will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 21814367.  The webcast and telephone replay will be available through October 27, 2011.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such forward-looking statements include, but are not limited to, references to (i) the belief that the interim data described in this press release, coupled with a very favorable safety profile to date, position setrobuvir as a very attractive agent to be included in future DAA combination regimens, (ii) Anadys' belief that the low incidence of viral breakthrough exhibited to date further characterizes setrobuvir's high barrier to resistance, and (iii) setrobuvir's potency and adverse event profile based on the interim data reported in this press release.  Such statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements.  For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that setrobuvir will not have unforeseen safety issues, will have favorable results in ongoing or future clinical trials or will receive regulatory approval. In addition, Anadys' results may be affected by competition from other biotechnology and pharmaceutical companies, its effectiveness at managing its financial resources, its ability to enter into transactions around its product candidates, its ability to successfully develop and market products, difficulties or delays in its non-clinical studies or clinical trials, difficulties or delays in manufacturing its clinical trials materials, the scope and validity of patent protection for its products, regulatory developments and its ability to obtain additional funding to support its operations.  Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-Q for the quarter ended June 30, 2011.  All forward-looking statements are qualified in their entirety by this cautionary statement.  Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Pegasys® and Copegus® are registered trademarks of Hoffman-La Roche Inc.

SOURCE Anadys Pharmaceuticals, Inc.

Website: http://www.anadyspharma.com
Contact: Investor, Amy Conrad of Anadys Pharmaceuticals, Inc.,
+1-858-530-3607, aconrad@anadyspharma.com; or Media, Ian Stone,
ian.stone@russopartnersllc.com, or David Schull, david.schull@russopartnersllc.com, +1-619-308-6541, both of Russo Partners, LLC
-0- Oct/13/2011 11:00 GMT
👍️0
vinsterr vinsterr 12 years ago
nice news I hope we get those 4$ a share if it gets aquired by a big company
👍️0
mak316 mak316 12 years ago
http://www.streetinsider.com/Analyst+Comments/Shares+of+Anadys+%28ANDS%29+Trade+Above+%241%3B+Analyst+Believes+Co.+Could+Get+a+Bid+Following+Setrobuvir+Data/6839646.html
👍️0
alvaroc2 alvaroc2 12 years ago
Good evening, this is my first message in ANDS forum, I put this good news about ANDS, regards.

nadys May Be Acquired After Releasing Data, William Blair Said
2011-10-06 13:14:07.429 GMT


By Clyde Eltzroth
Oct. 6 (Bloomberg) -- Anadys Pharmaceuticals may be acquired after release of top-line 12-week Setrobuvir Phase IIb data, expected next week/around mid-Oct., William Blair analyst Katherine Xu said in a note.
* 50% chance ANDS could be acquired following data: Xu
* Johnson & Johnson, Boehringer Ingelheim, GaxoSmithKline,
Novartis are potential suitors: Xu
* William Blair rates ANDS outperform, PT $4
* 7 buys, 3 holds, avg. PT $3: Bloomberg data
* ANDS closed above 10-, 100-DMAs
* ANDS down 34% YTD, Bloomberg San Diego Life Sciences (BSDLX)
down 21%

👍️0
JimsZ JimsZ 12 years ago
Couple very big buys at 1.03 - 80k and 25k. Looks like it's gonna continue to rise or someone throwing away a lot of money!
👍️0
Javed Javed 12 years ago
who scooped up the shares today???
👍️0
hm36tm hm36tm 12 years ago
Yes, big blocks of 200k shares are scooped up every day.
👍️0
amen amen 12 years ago
Making a move for Oct news.Notice the volume pick up.
👍️0
hm36tm hm36tm 13 years ago
ANDS could be the next VRUS in the Hepatitis C market

http://www.xconomy.com/san-diego/2011/09/06/dramatic-changes-in-hepatitis-c-treatment-expected-to-continue/

http://www.cnbc.com/id/44449463
👍️0
evenpar evenpar 13 years ago
No luck getting in at the ask .937 around 3;45...blew
right by me. Chart sure looks good.
👍️0
surf1944 surf1944 13 years ago
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
more coming, the recents must have gone well
Press Release Source: Anadys Pharmaceuticals, Inc. On Thursday September 15, 2011, 4:05 pm EDT

SAN DIEGO, Sept. 15, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS - News) announced today that it will present at the UBS Global Life Sciences Conference on Tuesday, September 20, 2011 at 4:30 p.m. EDT (1:30 p.m. PDT). The conference is being held at the Grand Hyatt in New York. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, setrobuvir and ANA773.

Dr. Worland will also present at the JMP Securities Healthcare Conference on Tuesday, September 27, 2011 at 2:00 p.m. EDT (11:00 a.m. PDT). The conference is being held at the St. Regis Hotel in New York.

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentations will be available approximately one hour after the live webcasts conclude and will be available through October 4, 2011 and October 11, 2011, respectively.
👍️0
enchanted enchanted 13 years ago
near 1 for sure
👍️0
Med.rare Med.rare 13 years ago
lets see a hard close over .85 that would be nice....
👍️0
enchanted enchanted 13 years ago
Train is Leaving
👍️0
enchanted enchanted 13 years ago
Good comeback with Volume
👍️0
enchanted enchanted 13 years ago
This stock seems promising although it is heading down everyday.
👍️0
porgyrusty porgyrusty 13 years ago
It seem that since the market starting regressing in July that quite a few of these small bio's are down. I guess I was referring to upcoming possible catalyst. Don't you think this is a good buying opportunity?
👍️0
knm_2 knm_2 13 years ago
Porgyrusty?

Are you smoking CRACK? ANDS has loss 40% since the first of Aug. 1st

👍️0
porgyrusty porgyrusty 13 years ago
Seems like some good thing happening for ANDS, now if the stock price would just follow.
👍️0
kookiekook kookiekook 13 years ago
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) made a presentation at the Stifel Nicolaus Healthcare Conference to Thursday, . Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, provided an overview of Anadys and its clinical development programs, setrobuvir and ANA773

Anadys is conducting a Phase IIb study of setrobuvir, the Company's DAA, added to pegylated interferon and ribavirin for the treatment of hepatitis C. the 12 week results of the 24 week trial will be released in early October. Prelimnary results of the study consisting of 100 patients on the cocktail and 50 recieving a placebo look very promising. The Company is also developing ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C and plans to initiate a Phase IIa study shortly.

Currently the company has $25million in cash and does not believe additional will be needed.

The full presentation can be heard on the Anadys web-site.
👍️0
surf1944 surf1944 13 years ago
Anadys' Setrobuvir Named One of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch

Press Release Source: Anadys Pharmaceuticals, Inc. On Wednesday September 7, 2011, 4:05 pm EDT

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq:ANDS - News) announced today that setrobuvir (ANA598), the Company's direct-acting antiviral (DAA) currently in Phase IIb development for hepatitis C, has been selected as one of Windhover's Top 10 Most Interesting Infectious Disease Projects to Watch.

"We are honored to have setrobuvir identified as a Top 10 infectious disease project," said Kevin Eastwood, Anadys' Senior Vice President of Corporate Development. "This recognition reflects the scarcity of later-stage development assets in hepatitis C and the strong desire on the part of companies to assemble combination regimens to treat this disease. With a readout next month of the 12-week data from an ongoing Phase IIb trial, Anadys has positioned setrobuvir as a well-characterized agent, ideally suited to complement other DAAs as the treatment of HCV evolves to a DAA combination treatment paradigm."

Setrobuvir was selected by independent experts at Windhover Information and Herndon Company. The selection criteria included the breadth of business development opportunities, the current size and growth of the targeted market, and the strength of science underlying the program. Many assets selected in this manner by Windhover in prior years have been the focus of subsequent attractive business transactions.

As a selected company, Anadys will present at Windhover's 6th Annual Therapeutic Area Partnerships conference November 30-December 2, 2011 in Boston, MA. Windhover is a leading provider of business information to senior executives in the pharmaceutical, biotechnology, and medical device industries.
👍️0
conix conix 13 years ago
ANDS in a Bottom Reversal

👍️0
db2469 db2469 13 years ago
Is that always a good thing for the shareholders?
DB
👍️0
enchanted enchanted 13 years ago
1.1 Million may be due to the limit order that people has placed. Seems like some merger/acquisition in progress.
👍️0
Chimaera Chimaera 13 years ago
TONS of buying...anyone know what is going on? PPS barely moved despite 1.1 million shares traded.
👍️0
enchanted enchanted 13 years ago
Seems Acquisition on work. A lot of buying.
👍️0
surf1944 surf1944 13 years ago
Anadys Pharmaceuticals Inc. (ANDS): Biotechnology Industry. Market cap of $42.89M. Net insider purchases over the last six months at 5.41M, which is 20.85% of the company's 25.92M share float. The stock has had a couple of great days, gaining 13.64% over the last week. The stock has performed poorly over the last month, losing 25%.

12 Cancer Stocks Being Snapped Up by Insiders

http://seekingalpha.com/article/288471-12-cancer-stocks-being-snapped-up-by-insiders?source=yahoo

http://www.insidercow.com/history/company.jsp?company=ands&B1=Search!
👍️0
enchanted enchanted 13 years ago
Looking good
👍️0
enchanted enchanted 13 years ago
Wondering how low this can go.
👍️0
oregon 1 oregon 1 13 years ago
This is a lot of volume for this stock. I think its because of the low float. Good buying today, especially for a down market.
👍️0
TH_Stockhunter TH_Stockhunter 13 years ago
Bought some here on $heff alert...

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65747060
👍️0
surf1944 surf1944 13 years ago
Anadys Pharma ANDS Wedbush Outperform $2

http://www.breifing.com/investor/calendars/upgrades-downgrades/
👍️0
timvic timvic 13 years ago
ANDS is trading in the range of $0.96 - $1.29 in the past 30 days.
Average True Range (Atr) indicates the volatility has increased for ANDS.
Commodity Channel Index (CCI) is bullish for ANDS.
ANDS formed a bullish Gap Up signal.
Money Flow Index (MFI) is bullish and moving up for ANDS.
ANDS formed a bullish Price & Exponential Moving Average Crossover signal.
ANDS formed a bullish Price & Simple Moving Average Crossover signal.
The 10-day simple moving average is bullish and moving up for ANDS.
ANDS formed a bullish Stochastic Crossover signal.
Average volume increase over 10% for ANDS.
👍️0
Hedge Starz Hedge Starz 13 years ago
im watching it again here. need to call their ir again to get timeframes.
👍️0
surf1944 surf1944 13 years ago
Anadys Pharma ANDS Brean Murray Hold
👍️0
Mick1 Mick1 13 years ago
News ANDS got a patent, don't know how significant this is.

http://finance.yahoo.com/news/Anadys-Announces-Issuance-of-prnews-2999387237.html?x=0&.v=1
👍️0

Your Recent History

Delayed Upgrade Clock